MetaCap

Nutriband Inc. (NTRB)

NASDAQ: NTRBHealth CareIndustrial SpecialtiesUSD

4.92-0.0801 (-1.60%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

NTRB stock chart

Technical analysis

Key statistics

All statistics
Market cap
$59.81M
EPS (TTM)
-$0.53
52-week range
2.80 – 9.19
Day range
4.84 – 5.22
Volume / Avg
7.00K / 70.61K
Beta
—
Next earnings
Dec 9, 2026

52-week range

$2.80$9.19

NTRB stock today

On Nov 20, NTRB ended the session at $4.92, shedding $0.0801 (1.60%), versus the S&P 500's 3.70% decline. Trading was light, with 7.00K shares changing hands, about 10% of the average daily volume. At this level, NTRB sits in the middle of its 52-week range of $2.80 to $9.19: 46.4% below the high, set on Sep 25, 2026 and 75.7% above the low.

NTRB is up 8.4% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 2.9%. Nutriband has posted a net loss over the last twelve months (EPS of -$0.53), so its P/E ratio is not meaningful. The company is scheduled to report Oct/2026 results on Dec 9.

Summary generated from market data by MetaCap's automated system. Methodology

About Nutriband

Company profile

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain.

Industry
Industrial Specialties
CEO
Mr. Gareth Sheridan
Headquarters
Orlando, FL

Financial highlights

Full financials

In fiscal 2026, Nutriband generated $2.0 million in revenue, down 4.8% from fiscal 2025, its first annual decline since 2020. Nutriband reported a net loss of $8.2 million, compared with a loss of $10.5 million a year earlier. Gross margin was 27.8% (down from 34.7%) and operating margin -408.4%.

Nutriband annual revenue, net income and EPS
Fiscal yearFY 2026FY 2025FY 2024FY 2023FY 2022
Revenue$2.04M$2.14M$2.09M$2.08M$1.42M
Growth-4.81%+2.60%+0.27%+46.23%+50.70%
Net income$-8.23M$-10.48M$-5.49M$-4.48M$-6.18M
EPS (diluted)$-2.58$-0.99$-0.69$-0.53$-0.80

Analyst forecast

Forecast

Consensus (1 analysts)

none

Avg. price target

$15.00+204.88%

  • Strong buy 0
  • Buy 1
  • Hold 0
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Next report
Dec 9, 2026
Last reported (Q2 2027)
Sep 4, 2026
EPS actual vs est.
$-0.07 vs —

NTRB news

All NTRB news

Nutriband peers

Health Care sector
NTRB peer companies
CompanyPrice% ChgMarket capCompare
APTAlpha Pro Tech Ltd.5.96-4.49%$61.17Mvs NTRB
COCHEnvoy Medical Inc. Class A6.700.00%$51.89Mvs NTRB
YDDLOne and One Green Technologies. Inc Class A0.910.00%$50.99Mvs NTRB
NTICNorthern Technologies International Corporation7.38-1.99%$71.09Mvs NTRB
CNXUConexeu Sciences Inc.1.55-25.48%$47.79Mvs NTRB
AGPUAxe Compute Inc.5.71-10.85%$77.94Mvs NTRB
LAKELakeland Industries Inc.8.29-0.48%$82.33Mvs NTRB
WBXWallbox N.V. Class A1.49-13.87%$36.14Mvs NTRB

Indexes, lists and sector

Nutriband stock FAQ

What is Nutriband's stock price today?

NTRB last traded at $4.92 as of Nov 20, 4:00 PM EST, down 1.60% on the day. Prices are delayed at least 15 minutes.

Does Nutriband pay a dividend?

No. Nutriband does not currently pay a regular cash dividend.

When is Nutriband's next earnings date?

Nutriband is expected to report earnings on Wednesday, December 9, 2026.

Who is Nutriband's CEO?

Mr. Gareth Sheridan is the chief executive officer of Nutriband Inc..

Has NTRB ever split its stock?

Yes. The most recent NTRB stock split was a 1166-for-1000 split on Aug 12, 2022.

What is the NTRB 52-week high?

The 52-week high for NTRB is $9.19 and the 52-week low is $2.80. The stock is currently 46.4% below its high.

Compare NTRB